By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – French firms Hybrigenics and Servier today announced a licensing and research deal targeting deubiquitinating enzymes, or DUBs, for various diseases that could result in the development of companion diagnostics.

Under the terms of the deal, Hybrigenics will identify and validate new targets among DUBs for cancer, diseases in neurology, psychiatry, rheumatology, and ophthalmology, as well as diabetes, and cardiovascular illness.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.